Tamer Elbaz

Tamer Elbaz

Auto-generated profile, based on publicly available information

Tamer Elbaz

Endemic Medicine Department, Faculty of Medicine, Cairo University, Giza, Egypt

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2017 in The Lancet Gastroenterology & Hepatology
Verified
Journal Article
Closed access
JYJu Dong Yang
Ju Dong Yang
EMEssa A Mohamed
Essa A Mohamed
AAAshraf O Abdel Aziz
Ashraf O Abdel Aziz
HSHend I Shousha
Hend I Shousha
MHMohamed B Hashem
Mohamed B Hashem
LRLewis R Roberts
Lewis R Roberts

1 September 2013 in Journal of Advanced Research
Verified
Journal Article
Open access
TETamer Elbaz
Tamer Elbaz
GEGamal Esmat
Gamal Esmat
Schistosomiasis is an endemic disease in Egypt caused by the trematode Schistosoma which has different species. Hepatic schistosomiasis represents the best known form of chronic disease with a wide range of clinical manifestations. The pathogenesis of schistosomiasis is related to the host cellular immune response. This leads to granuloma formation and neo angiogenesis with subsequent periportal fibrosis manifested as portal hypertension, splenomegaly and esophageal varices. Intestinal schistosomiasis is another well identified form of chronic schistosomal affection. Egg deposition and granuloma formation eventually leads to acute then chronic schistosomal colitis and is commonly associated with polyp formation. It frequently presents as abdominal pain, diarrhea, tenesmus and anal pain. Definite diagnosis of schistosomiasis disease depends on microscopy and egg identification. Marked progress regarding serologic diagnosis occurred with development of recent PCR techniques that can confirm schistosomal affection at any stage. Many antischistosomal drugs have been described for treatment, praziquantel being the most safe and efficient drug. Still ongoing studies try to develop effective vaccines with identification of many target antigens. Preventive programs are highly needed to control the disease morbidity and to break the cycle of transmission.

1 September 2013 in Journal of Advanced Research
Verified
Journal Article
Open access
RBRashad S. Barsoum
Rashad S. Barsoum
GEGamal Esmat
Gamal Esmat
TETamer El-Baz
Tamer El-Baz
The clinical manifestations of schistosomiasis pass by acute, sub acute and chronic stages that mirror the immune response to infection. The later includes in succession innate, TH1 and TH2 adaptive stages, with an ultimate establishment of concomitant immunity. Some patients may also develop late complications, or suffer the sequelae of co-infection with other parasites, bacteria or viruses. Acute manifestations are species-independent; occur during the early stages of invasion and migration, where infection-naivety and the host's racial and genetic setting play a major role. Sub acute manifestations occur after maturity of the parasite and settlement in target organs. They are related to the formation of granulomata around eggs or dead worms, primarily in the lower urinary tract with Schistosoma haematobium, and the colon and rectum with Schistosoma mansoni, Schistosoma japonicum, Schistosoma intercalatum and Schistosoma mekongi infection. Secondary manifestations during this stage may occur in the kidneys, liver, lungs or other ectopic sites. Chronic morbidity is attributed to the healing of granulomata by fibrosis and calcification at the sites of oval entrapment, deposition of schistosomal antigen-antibody complexes in the renal glomeruli or the development of secondary amyloidosis. Malignancy may complicate the chronic lesions in the urinary bladder or colon. Co-infection with salmonella or hepatitis viruses B or C may confound the clinical picture of schistosomiasis, while the latter may have a negative impact on the course of other co-infections as malaria, leishmaniasis and HIV. Prevention of schistosomiasis is basically geared around education and periodic mass treatment, an effective vaccine being still experimental. Praziquantel is the drug of choice in the treatment of active infection by any species, with a cure rate of 80%. Other antischistosomal drugs include metrifonate for S. haematobium, oxamniquine for S. mansoni and Artemether and, possibly, Mirazid for both. Surgical treatment may be needed for fibrotic lesions.

17 June 2014 in Surgical Endoscopy
Verified
Journal Article
Closed access
PDF file
AAAshraf Abdelaziz
Ashraf Abdelaziz
TETamer Elbaz
Tamer Elbaz
HSHend Ibrahim Shousha
Hend Ibrahim Shousha
SMSherif Mahmoud
Sherif Mahmoud
MIMostafa Ibrahim
Mostafa Ibrahim
MNMohamed Nabeel
Mohamed Nabeel

29 November 2017 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
HOHeba Omar
Heba Omar
WAW. El Akel
W. El Akel
TET. Elbaz
T. Elbaz
MEMohamed El-Kassas
Mohamed El-Kassas
KEK. Elsaeed
K. Elsaeed
YSY. El Shazly
Y. El Shazly

11 March 2018 in Expert Review of Anti-infective Therapy
Verified
Journal Article
Closed access
MEMohamed El-Kassas
Mohamed El-Kassas
TETamer Elbaz
Tamer Elbaz
AEAisha Elsharkawy
Aisha Elsharkawy
HOHeba Omar
Heba Omar
GEGamal Esmat
Gamal Esmat
Currently, direct-acting antivirals (DAAs) are considered the ideal choice for the treatment of chronic HCV patients due to their proven efficacy (SVR> 90%), and minimal adverse effects. Egypt launched a large treatment program aimed at providing treatment coverage for Egyptian HCV- infected patients. Areas covered: This review covers the treatment and prevention efforts made by the Egyptian National Committee for the Control of Viral Hepatitis (NCCVH) with the available model of care for HCV patients in Egypt, in addition to the barriers that prevent elimination of HCV from Egypt. Expert commentary: Egypt could provide a model for establishing the largest HCV management system aimed at eliminating HCV from the country with the highest worldwide prevalence. Despite the huge efforts and achieved results in combating the HCV epidemic in Egypt, certain improvements are needed in order to attain HCV elimination, such as the development of an enhanced screening program working in parallel to the present treatment options.